{"id":"NCT00117598","sponsor":"Pfizer","briefTitle":"Study Evaluating Temsirolimus (CCI-779) In Mantle Cell Lymphoma (MCL)","officialTitle":"An Open-Label, Randomized, Phase 3 Trial Of Intravenous Temsirolimus (CCI-779) At Two Dose Levels Compared To Investigator's Choice Therapy In Relapsed, Refractory Subjects With Mantle Cell Lymphoma (MCL)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2005-05","primaryCompletion":"2007-08","completion":"2011-01","firstPosted":"2005-07-07","resultsPosted":"2012-03-06","lastUpdate":"2015-03-30"},"enrollment":169,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Lymphoma"],"interventions":[{"type":"DRUG","name":"Temsirolimus (CCI-779)","otherNames":[]},{"type":"DRUG","name":"Temsirolimus (CCI-779)","otherNames":[]},{"type":"DRUG","name":"Investigator's choice","otherNames":[]}],"arms":[{"label":"A","type":"EXPERIMENTAL"},{"label":"B","type":"EXPERIMENTAL"},{"label":"C","type":"ACTIVE_COMPARATOR"}],"summary":"This is an open-label, randomized trial in relapsed refractory subjects with mantle cell lymphoma (MCL).","primaryOutcome":{"measure":"Progression-Free Survival (PFS)","timeFrame":"Baseline, every 8 weeks up to Year 1, then every 12 weeks up to Year 2, and then every 6 months until tumor progression or death (up to Year 5)","effectByArm":[{"arm":"Temsirolimus 175/75 mg","deltaMin":4.8,"sd":null},{"arm":"Temsirolimus 175/25 mg","deltaMin":3.7,"sd":null},{"arm":"Investigator's Choice","deltaMin":1.8,"sd":null}],"pValues":[{"comp":"OG000 vs OG002","p":"<0.0001"},{"comp":"OG001 vs OG002","p":"<0.0001"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":7,"exclusionCount":3},"locations":{"siteCount":73,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Chile","China","France","Germany","Italy","Netherlands","Poland","Spain","Sweden","Switzerland","United Kingdom"]},"refs":{"pmids":["25938001"],"seeAlso":["https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=3066K1-305&StudyName=Study%20Evaluating%20Temsirolimus%20%28CCI-779%29%20In%20Mantle%20Cell%20Lymphoma%20%28MCL%29"]},"adverseEventsSummary":{"seriousAny":{"events":34,"n":57},"commonTop":["Thrombocytopenia","Asthenia","Anemia","Neutropenia","Fever"]}}